Will Laurus Labs Sustain Its Turnaround Momentum in FY26?
About Laurus Labs
Laurus Labs Ltd is a Hyderabad-based pharmaceutical and biotechnology company engaged in manufacturing APIs, formulations, and contract research. It supplies to major global pharma firms across 50+ countries.
The company’s Q2 FY26 performance indicates strong execution in formulations and CRAMS, with margin recovery aided by backward integration and operational cost control.
Financial Highlights (Q2 FY26)
| Metric | Q2 FY26 | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹1,615 Cr | +11% | +6% |
| EBITDA | ₹365 Cr | +18% | +7% |
| EBITDA Margin | 22.6% | vs 21.3% | vs 22.1% |
| Net Profit | ₹245 Cr | +20% | +8% |
Revenue ₹1,615 Cr — boosted by demand for ARV APIs and synthesis contracts.
EBITDA ₹365 Cr — supported by improved plant utilization and cost efficiencies.
EBITDA Margin 22.6% — rising due to better product mix and efficiency in operations.
Net Profit ₹245 Cr — reflects strong operating leverage and financial discipline.
Traders tracking pharma trends can follow Nifty Expiry Tip.
Peer Comparison
| Company | Revenue (₹ Cr) | EBITDA Margin |
|---|---|---|
| Laurus Labs | 1,615 | 22.6% |
| Divi’s Labs | 2,715 | 32.7% |
| Granules India | 1,290 | 17.3% |
Laurus continues to strengthen its formulation and synthesis verticals while optimizing its API segment.
Strengths & Weaknesses
Strengths
|
Weaknesses
|
Focus on CRAMS partnerships will continue to drive stability in earnings.
Opportunities & Threats
|
|
Laurus is expected to maintain stable growth as operational leverage improves further.
Valuation & Investment View
- Short-term: Stable as margins expand.
- Medium-term: Growth visibility from CRAMS.
- Long-term: Structural opportunity in global formulations.
Track setups linked to BankNifty Expiry Tip.
Investor Takeaway
Indian-Share-Tips.com Nifty Expert Gulshan Khera, CFP®, emphasizes that Laurus’s integrated model positions it well for consistent growth. Explore more insights at Indian-Share-Tips.com, which is a SEBI Registered Advisory Services.
Related Queries on Laurus Labs
- What drives Laurus’s margin expansion?
- How is CRAMS contributing to profitability?
- Is the ARV slowdown fully priced in?
SEBI Disclaimer: The information provided in this post is for informational purposes only and should not be construed as investment advice. Readers must perform their own due diligence and consult a registered investment advisor before making any investment decisions. The views expressed are general in nature and may not suit individual investment objectives or financial situations.
